

Scott J Antonia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11619399/publications.pdf>

Version: 2024-02-01

83
papers

38,839
citations

57681

46
h-index

78623

77
g-index

83
all docs

83
docs citations

83
times ranked

39058
citing authors

#	ARTICLE	IF	CITATIONS
1	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
2	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.	0.9	7
3	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
4	Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 425-435.	0.4	35
5	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38.	0.9	30
6	Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 3501-3510.	0.7	13
7	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 419-427.	0.5	33
8	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 1165-1184.	1.1	2
9	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLCâ€“an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	0.5	323
10	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Nonâ€“Smallâ€“Cell Lung Cancer (PACIFIC). <i>Clinical Lung Cancer</i> , 2021, 22, 549-561.	1.1	25
11	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
12	Abstract 1635: Sirt2 blockade promotes T cell metabolism and restores the anti-tumor immunity. , 2021, , .		0
13	Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. <i>Nature Medicine</i> , 2021, 27, 1410-1418.	15.2	168
14	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCâ€“Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293.	0.5	328
15	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	0.5	181
16	The immunotherapeutic landscape in nonâ€“small cell lung cancer and its surgical horizons. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1616-1623.	0.4	21
17	A communityâ€“based lung cancer rapid tissue donation protocol provides highâ€“quality drugâ€“resistant specimens for proteogenomic analyses. <i>Cancer Medicine</i> , 2020, 9, 225-237.	1.3	11
18	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446

#	ARTICLE	IF	CITATIONS
19	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1395-1408.	5.1	247
20	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	3.4	388
21	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1670-1680.	5.1	125
22	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	0.5	69
23	Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. <i>European Journal of Cancer</i> , 2019, 109, 154-161.	1.3	64
24	Phase I/II Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6623-6632.	3.2	96
25	Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 517-527.	2.0	39
26	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	0.5	241
27	Durvalumab in Stage III Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 868-870.	13.9	33
28	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
29	Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program. <i>Patient Education and Counseling</i> , 2018, 101, 703-710.	1.0	6
30	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	7.7	725
31	Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 2342-2350.	13.9	2,150
32	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1853-1862.	2.0	21
33	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 29.	0.7	24
34	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky021.	1.4	92
35	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018, 101, 201-209.	1.3	41
36	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)., 2018, 6, 75.		188

#	ARTICLE	IF	CITATIONS
37	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. Expert Opinion on Biological Therapy, 2017, 17, 305-312.	1.4	42
38	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. Journal of Neuro-Oncology, 2017, 133, 331-338.	1.4	107
39	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncology, The, 2017, 18, 31-41.	5.1	845
40	A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia, 2017, 19, 530-536.	2.3	71
41	Durvalumab after Chemoradiotherapy in Stage III Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 1919-1929.	13.9	3,261
42	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncology, The, 2017, 18, 1261-1273.	5.1	356
43	Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment. , 2017, 5, 54.		30
44	A Bayesian pick-the-winner design in a randomized phase II clinical trial. Oncotarget, 2017, 8, 88376-88385.	0.8	6
45	Immunotherapy: Beyond Antiâ€“PD-1 and Antiâ€“PD-L1 Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e450-e458.	1.8	35
46	The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. BMC Cancer, 2016, 16, 176.	1.1	87
47	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 903-910.	1.1	6
48	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 883-895.	5.1	1,091
49	HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 4119-4132.	3.2	266
50	Immunotherapy: Beyond Antiâ€“PD-1 and Antiâ€“PD-L1 Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e450-e458.	1.8	34
51	A phase I study of indoximod in patients with advanced malignancies. Oncotarget, 2016, 7, 22928-22938.	0.8	126
52	Nonâ€“Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. Journal of Thoracic Oncology, 2015, 10, 974-984.	0.5	127
53	A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model. Breast Cancer: Targets and Therapy, 2015, 7, 389.	1.0	8
54	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology, The, 2015, 16, 257-265.	5.1	1,269

#	ARTICLE	IF	CITATIONS
55	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB / Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
56	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 1627-1639.	13.9	7,973
57	Genetically Modified Dendritic Cell Vaccines for Solid Tumors. , 2014, , 273-282.		0
58	Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. Clinical Cancer Research, 2014, 20, 6258-6268.	3.2	88
59	Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. OncoImmunology, 2013, 2, e23428.	2.1	74
60	A new role for NF- κ B in immunosurveillance and its implications for cancer immunotherapy. OncoImmunology, 2013, 2, e25963.	2.1	3
61	Immunotherapy in Lung Cancer: α B7-Bombers and Other New Developments. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 810-821.	0.8	6
62	Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biology and Therapy, 2013, 14, 860-868.	1.5	83
63	Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.. Journal of Clinical Oncology, 2013, 31, 3002-3002.	0.8	47
64	Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2013, 31, TPS3112-TPS3112.	0.8	2
65	Combination of External Beam Radiotherapy (EBRT) With Intratumoral Injection of Dendritic Cells as Neo-Adjuvant Treatment of High-Risk Soft Tissue Sarcoma Patients. International Journal of Radiation Oncology Biology Physics, 2012, 82, 924-932.	0.4	109
66	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	13.9	10,727
67	Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF. Anticancer Research, 2011, 31, 3193-204.	0.5	26
68	INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opinion on Biological Therapy, 2010, 10, 983-991.	1.4	107
69	Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biology and Therapy, 2010, 10, 983-993.	1.5	135
70	Phase II Trial of B7-1 (CD-86) Transduced, Cultured Autologous Tumor Cell Vaccine Plus Subcutaneous Interleukin-2 for Treatment of Stage IV Renal Cell Carcinoma. Journal of Immunotherapy, 2008, 31, 72-80.	1.2	71
71	Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody. Journal of Clinical Oncology, 2007, 25, 876-883.	0.8	458
72	A phase-I Trial Using a Universal GM-CSF-producing and CD40L-expressing Bystander Cell Line (GM.CD40L) in the Formulation of Autologous Tumor Cell-based Vaccines for Cancer Patients with Stage IV disease. Annals of Surgical Oncology, 2007, 14, 869-884.	0.7	48

#	ARTICLE	IF	CITATIONS
73	Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 878-887.	3.2	397
74	A GM-CSF/CD40L Producing Cell Augments Anti-tumor T Cell Responses. <i>Journal of Surgical Research</i> , 2005, 125, 173-181.	0.8	18
75	Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. <i>Journal of Clinical Investigation</i> , 2004, 114, 280-290.	3.9	632
76	Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma. <i>Laboratory Investigation</i> , 2003, 83, 1457-1466.	1.7	107
77	Cell-based immune therapy for metastatic renal cancer. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 837-849.	1.1	2
78	Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase. <i>Science</i> , 2002, 297, 1867-1870.	6.0	946
79	Phase I Trial of a B7-1 (CD80) Gene Modified Autologous Tumor Cell Vaccine in Combination With Systemic Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 2002, 167, 1995-2000.	0.2	112
80	Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. <i>International Journal of Cancer</i> , 2002, 101, 151-155.	2.3	343
81	B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. <i>World Journal of Urology</i> , 2000, 18, 157-163.	1.2	13
82	Attachment of tumor cells to endothelial monolayers: Detection of surface molecules involved in cell-cell binding. <i>Clinical Immunology and Immunopathology</i> , 1989, 53, 281-296.	2.1	5
83	Adherence of tumor cells to endothelial monolayers: Inhibition by lymphokines. <i>Cellular Immunology</i> , 1985, 95, 247-257.	1.4	4